TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Development of Dietary Supplements for Mood Symptoms in Postpartum

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 45~* The subject, as reported by them, should be in a good health.~* The subject is not taking any medication.~* The subject is not taking any investigational medicinal product within 8 weeks.~* BMI 19 to 40 (kg/m2)~* Resting pulse between 45 and 100 bpm~* Systolic blood pressure between 91 and 139 mmHg (inclusive)~* Diastolic blood pressure between 51 and 90 mmHg (inclusive)~Exclusion Criteria:~* The subject has been diagnosed with any axis 1 and 2 disorders based on Structured Clinical Interview (SCID) for DSM-IV interview.~* Substance abuse disorder~* Subjects who have been smoking in the past 5 years.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Postpartum with crying spells-Full dose (Type: EXPERIMENTAL): Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.~Intervention: Full dose dietary supplement Motherwell
- Day-5 postpartum - Full dose (Type: EXPERIMENTAL): Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell
- Day-5 postpartum - Half dose (Type: EXPERIMENTAL): Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Half dose dietary supplement Motherwell
- Day-5 postpartum - Quarter dose (Type: EXPERIMENTAL): Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Quarter dose dietary supplement Motherwell
- Day-5 postpartum - Control (Type: OTHER): Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.~Intervention: Control protein to compare with Motherwell

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with pathologically clear invasive breast cancer between 2003 and 2018;~* Female,18-75 years old;~* Measurable metastatic lesion according to RECIST 1.1 evaluation criteria;~* The first-line chemotherapy regimen is a breast cancer combination or single-agent chemotherapy regimen recommended by the NCCN guidelines;~* First-line chemotherapy is effective (according to RECIST1.1 evaluation criteria, the efficacy is evaluated as complete response (CR), partial response (PR), or steady state (SD));~* After the last cycle of first-line chemotherapy, patients should still be in a state of no progress for at least 4 weeks;~* Patients' Karnofsky performance status (KPS) scores were ≥70.~Exclusion Criteria:~* Unmeasurable metastatic lesion according to RECIST 1.1 evaluation criteria.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MCT Group (Type: None): People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
- MET Group (Type: None): People who received endocrine therapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
- Observation Group (Type: None): People who didn't receive any maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Contingency Management for Smoking in Substance Abusers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of substance abuse or dependence by DSM-IV criteria~* in residential treatment at one particular agency~* currently smoking at least 10 cigarettes per day for the past 6 months~Exclusion Criteria:~* hallucinating or delusional or marked organic impairment (to the point of impairing ability to understand informed consent) according to medical records~* current use of nicotine replacement therapy, Zyban, or any other smoking cessation treatment~* medical exclusions for NRT: pregnant or nursing; treatment in the last 3 months for unstable angina, severe congestive heart failure, uncontrolled hypertension; lung cancer; supplemental oxygen; history of adverse reactions to NRT; allergies to adhesive; or any severe skin disease that requires treatment (e.g., psoriasis or eczema).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contingency Management (CM) (Type: EXPERIMENTAL): Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
- Noncontingent Reinforcement (NR) (Type: ACTIVE_COMPARATOR): Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CP CML of ≤6 months (from initial diagnosis); Diagnosis of CP CML with molecular confirmation by detection of BCR-ABL rearrangement at screening (cytogenetic assessment for Ph is not required for enrollment; however, patients with known Ph- CML prior to registration are not eligible for this study)~* Age ≥20 years~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1~* Adequate Liver and Renal Function~Exclusion Criteria:~* Any prior medical treatment for CML, including TKIs, with the exception of hydroxyurea treatment, which is permitted for up to 6 months prior to registration~* Any past or current CNS involvement, including leptomeningeal leukemia~* Extramedullary disease only~* Major surgery or radiotherapy within 14 days prior to registration~* History of clinically significant or uncontrolled cardiac disease~* Patients with active, uncontrolled bacterial, fungal, or viral infection~* Recent or ongoing clinically significant GI disorder~* History of another malignancy within 5 years prior to registration~* Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval~* Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations~* Participation in other studies involving investigational drug(s) within 30 days or 5 half-lives of investigational product, whichever is longer, prior to registration and/or during study participation~* Other severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or interfere with the interpretation of study results~* Investigational site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosutinib (Type: EXPERIMENTAL): Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 85~* Histologically or cytologically confirmed advanced or metastatic solid tumors~* Patients will be received femoral venepuncture for apheresis by cell separator, which is the necessary process to perform following adoptive cell immunotherapy.~* Estimated life expectancy \> 3 months~* Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR \<1.5 (unless patient is receiving warfarin in which case PT-INR must be \<3), PTT \<1.5X ULN~* Adequate renal and hepatic function, with serum creatinine \< 1.5 mg/dL, bilirubin \< 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.~Exclusion Criteria:~* known conditions associated with high risk of bleeding, known history of hemorrhagic diathesis~* Platelet count \< 50 000 G/L~* Active bleeding~* Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.~* Patients with obstructive jaundice~* Patients with Spleen hyperfunction~* Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.~* Pregnant or breast-feeding women，or lack of effective contraceptive treatment for women of childbearing age.;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 10mg daily (Type: EXPERIMENTAL): orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
- Rivaroxaban 20mg daily (Type: EXPERIMENTAL): orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
- Low-molecular-weight heparin (Type: ACTIVE_COMPARATOR): subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven Diffuse Large B-Cell Lymphoma (DLBCL).~* Relapsed or refractory to combination chemotherapy for DLBCL that contains rituximab and an anthracycline, and one additional combination chemotherapy or stem cell transplant.~* Measurable DLBCL disease by computed tomograph (CT) / magnetic resonance imagining (MRI).~* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.~Exclusion Criteria:~* Diagnosis of lymphoma histologies other than DLBCL.~* History of malignancies, other than DLBCL, unless the patient has been disease free for 3 years or more.~* Eligible for autologous stem cell transplant.~* Known seropositive for, or history of, active human immunodeficiency virus (HIV) hepatitis B virus (HBV), hepatitis C virus (HCV)~* Neuropathy grade 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
- Investigators Choice (Type: ACTIVE_COMPARATOR): One of the following:~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation；~Exclusion Criteria:~1. Bronchial asthma;~2. Allergic to N-acetyl-L-cystein

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- N-acetyl-L-cysteine group (Type: EXPERIMENTAL): Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, or their legally authorized representative, must voluntarily provide written IRB-approved informed consent.~* Males and females, 18 years of age or older at the time of enrollment.~* Patients must meet the diagnostic criteria for HPS (at least 5 of the following): fever, splenomegaly, cytopenia involving ≥2 cell lines (Hemoglobin \<9 g/dL; platelets \<100,000/μL; absolute neutrophil count \<1000/μL), hypertriglyceridemia or hypofibrinogenemia, tissue demonstration of hemophagocytosis, low or absent NK (Natural Killer) cell activity, serum ferritin ≥3000 ug/L, soluble IL-2 receptor (CD25) \>2400 U/mL.~* In the investigator's opinion, the patient has the ability to participate fully in the study, and comply with all its requirements.~Exclusion Criteria:~* CNS (Central Nervous System) involvement~* Malabsorption~* Known secondary HPS (Hemophagocytic Syndrome) that is otherwise treatable (e.g. non-Hodgkin's lymphoma).~* Pregnant or lactating female: all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment; lactating females must discontinue breast feeding.~* Estimated creatinine clearance \<15mL/min~* Has received any prior systemic therapy, excluding corticosteroids, within 7 days (or 5 half-lives) of treatment.~* No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ. Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies.~* Active hepatitis B or hepatitis C or known HIV infection~* Known (and biopsy-confirmed) liver cirrhosis; or, a reported history of liver cirrhosis with a Model for End-stage Liver Disease (MELD) score \>20.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months of age or younger at randomization (child must be randomized on or before their 6-month birthday)~* Male or female Native American~* General state of good health~* Written informed consent obtained from the participant's parent(s) or legal guardian~Exclusion Criteria:~* Gestational age less than or equal to 35 weeks~* Chronic lung disease of prematurity~* A bleeding diathesis that would preclude IM injections~* Hospitalization at the time of randomization (unless discharge is anticipated within 10 days)~* Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection~* A documented wheezing episode before enrollment~* Known renal impairment~* Known hepatic dysfunction~* Clinically significant congenital anomaly of the respiratory tract~* Chronic seizure or evolving or unstable neurologic disorder~* Congenital heart disease (CHD) (children with uncomplicated CHD \[e.g., Patent ductus arteriosus, small septal defect\] and children with complicated CHD who are currently anatomically and hemodynamically)~* Known immunodeficiency~* Mother with human immunodeficiency virus infection (unless the child has been proven to be not infected)~* Known allergy to Ig products~* Receipt of palivizumab, Respiratory syncytial virus immunoglobulin, intravenous (RSV-IGIV), or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B immunoglobulin, IVIG) within 3 months prior to randomization~* Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)~* Previous receipt of RSV vaccines~* Participation in other investigational drug product studies~* Any medical or social condition which, in the opinion of the investigator, would adversely affect monitoring the infant~* Inability to complete the study follow-up period through up to 5 years of age

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive IM dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
- Motavizumab (Type: ACTIVE_COMPARATOR): Participants will receive IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-Defense Training in Women With Trauma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women ages 21-65 years~2. History of physical and/or sexual violence, with subsequent interpersonal or psychological distress (e.g., depression or anxiety) related to this history.~Exclusion Criteria:~1. Substance abuse in the past 6 months~2. Significant medical conditions that would preclude safe participation in the study~3. High levels of depression with significant suicide risk~4. Pregnant women~5. Active symptoms of psychosis or psychiatric instability~6. History of assaultive behavior or is judged to be at potential risk to assault others.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Life skills and self-defense training (Type: EXPERIMENTAL): Women will participate in a therapeutic group which covers education, skills, and empowerment activities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gastrectomy, Eating Behaviour and GLP-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • At least 3 months post completion of treatment for gastric cancer, or prophylactic gastrectomy~  * Aged at least 18 years~ * Able to tolerate an oral glucose tolerance test~ * Able to understand and retain all information regarding the study and give informed consent.~ * Willing to receive an infusion of human albumin solution~Exclusion Criteria:~* • Have a diagnosis of diabetes~  * Have a history of untreated anaemia in the last 3 months~ * Be aged under 18 years~ * Have active gastric cancer~ * Be pregnant or attempting to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of 1% human albumin in normal saline.
- Exendin (Type: EXPERIMENTAL): Infusion of Exendin 9-39 in 1% human albumin in normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete